18
Executive Leadership

Partnership: It’s what turns services into solutions

Mission

We are a full service, global pharmaceutical CRO lab that provides high quality service to our clients and provides opportunities for our employees in grow a career in a healthy work environment.

Vision

To become one of the best CROs in the world by providing the best service possible, using the best technical know-how at a reasonable value, to enable our clients to develop life-saving medications.

Values

Quality We are committed to excellence in the results we achieve, and how we achieve them.

Integrity Being honest, reliable and accountable in our words and behavior, doing the right things for our clients, company, community, and ourselves.

Respect for people. Promote a diverse culture and commitment to mutually respect our teammates, our customers, and people around us.

Collaboration Working together to achieve common goals is the foundation of our success; seek input and listen, and be flexible and responsive.

Song Li, Ph.D.

Song Li, Ph.D.

Founder and Honorary Chairman, Frontage Holdings Corp. and CEO, Frontage Laboratories, Inc.
Song Li, Ph.D.

Song Li, Ph.D.

Founder and Honorary Chairman, Frontage Holdings Corp. and CEO, Frontage Laboratories, Inc.

Dr. Song Li founded Frontage Laboratories in 2001 with the ambition of building a client-focused organization to help solve the most complex drug development challenges. Prior to Frontage, Dr. Li held management positions at Great Valley Pharmaceuticals and Wyeth. During this time, he led numerous projects related to the development of pharmaceutical products.

Dr. Li has authored more than 15 scientific publications spanning a wide range of topics, including chiral separations, drug-protein interactions, pharmacokinetics, and analytical chemistry. Importantly, Dr. Li has been the recipient of numerous awards, most recently Healthcare CEO award from Philadelphia Alliance for Capital and Technologies, Ernst & Young Entrepreneur of the Year Award,  the “Realizing the American Dream” award from the Pennsylvania Welcoming Society, and the Outstanding 50 Asian Americans in Business Award from the AABDC.

Dr. Li earned a doctor of philosophy degree in analytical chemistry from McGill University and a bachelor of science degree in chemistry from Zhengzhou University in China.

 

linkedin logo 150x150 - Song Li, Ph.D.

 

Read Full Bio
Zeke Li, M.D.

Zeke Li, M.D.

CEO, Frontage Holdings Corp. and SVP, Frontage Laboratories, Inc.
Zeke Li, M.D.

Zeke Li, M.D.

CEO, Frontage Holdings Corp. and SVP, Frontage Laboratories, Inc.

Dr. Zeke Li is responsible for global project management functions and the company’s corporate strategy. As one of the founders and board members of Frontage, Dr. Li has more than 20 years of related experience that began with post-doctoral training at the National Institutes of Health. Prior to Frontage, he served as Group Leader, Preclinical and Pharmacology for Scios Inc., a Johnson and Johnson company. In recent years, Dr. Li has interacted extensively with Chinese biopharmaceutical companies on novel and generic development projects. With in-depth experience in research and development of small molecules, peptides and protein drugs, he has authored and co-authored more than 40 scientific papers and patents.

Dr. Li received his medical degree and a master’s degree in pathology from Norman Bethune University of Medical Sciences in China. He earned a doctor of philosophy degree in pathology from McGill University.

linkedin logo 150x150 - Zeke Li, M.D.

Read Full Bio
Andrew Wang

Andrew Wang

Chief Financial Officer (CFO)
Andrew Wang

Andrew Wang

Chief Financial Officer (CFO)

Mr. Wang has more than 27 years of extensive experience in financial service and accounting aspect, include corporate finance and treasury management, corporate accounting, compliance, internal control and corporate budgetary management. Mr. Wang is the Chief Financial Officer of the Company and is responsible for the management of all aspects of the Group’s finance and treasury matters.  Prior to joining Frontage in October 2020, Mr. Wang was the Chief Financial Officer of Frontida Biopharm, Inc., a contract development and manufacturing organization in the United States of America. Previously, he was the Chief Financial Officer and the Director of the Board of Sky Solar Holdings, Ltd. a NASDAQ listed company.  Before that, he served as finance director or controller in different multinational companies, mainly in the Asia Pacific area.

 

Mr. Wang is a professional accountant, having been a member of the China Institute of Certified Public Accountant since August 1995.  Mr. Wang was awarded an Executive Master of Business Administration by Washington University in St. Louis in December 2004.  In July 1993, he was awarded a Bachelor’s degree in Accounting by University of Shanghai for Science and Technology.

linkedin logo 150x150 - Andrew Wang

Read Full Bio
Dongmei Wang, Ph.D.

Dongmei Wang, Ph.D.

Executive Vice President, Global CMC Services
Dongmei Wang, Ph.D.

Dongmei Wang, Ph.D.

Executive Vice President, Global CMC Services

With more than 20 years of pharmaceutical and biotech industrial experience, Dr. Wang is responsible for the Global CMC (Chemistry Manufacture & Control) Services at Frontage, including analytical services, formulation development, and manufacturing of GLP preclinical tox batches & GMP clinical trial materials. Products includes oral formulations, topical and sterile injections & ophthalmic formulations for IND, NDA and ANDA filings. Prior to joining Frontage in February 2007, Dr. Wang served as the director of Analytical Chemistry at NovaDel Pharma Inc., where she led teams providing support for NDA product development, clinical supply manufacturing, CMC sections of 505(b)(2) filings, and technology transfer to commercial manufacturing sites. Prior to NovaDel, Dr. Wang headed Pharmaceutical Analysis and Control department at Therics Inc. to support 3D printing product development for 510(k) and IND filings. Earlier in her career, Dr. Wang was a lecturer at the Graduate University of Chinese Academy of Science.

Dr. Wang earned a PhD degree in Chemistry from Iowa State University, followed by postdoctoral research at the University of Chicago. She received a MS in Chemical Engineering from China Institute of Atomic Energy and a BS in Chemistry from Peking University in China.

linkedin logo 150x150 - Dongmei Wang, Ph.D.

Read Full Bio
John Lin, Ph.D.

John Lin, Ph.D.

Executive Vice President, Bioanalytical and Biologics Services
John Lin, Ph.D.

John Lin, Ph.D.

Executive Vice President, Bioanalytical and Biologics Services

As Executive Vice President, Bioanalytical and Biologics Services, Dr. John Lin leads operations for the company’s global bioanalytical labs. Before joining Frontage, he served as a business leader in AstraZeneca’s global drug metabolism and pharmacokinetics (DMPK) division. Prior to AstraZeneca, Dr. Lin was Laboratory Director for Avantix Laboratories.

With more than 20 years of experience, Dr. Lin’s current research focus is in the area of bioanalytical method development and validation, dry blood spot (DBS) sampling with LC-MS/MS analysis, and biomarker quantification using LC-MS/MS. He has contributed to more than 20 research publications covering the development and validation of LC-MS/MS methods for the determination of small and large molecules in biological matrices, four book chapters and one technical patent. He is the invited reviewer for several international journals including the Journal of Pharmaceutical Biomedical Analysis (JPBA) and Journal of Chromatography B (JCB).

Dr. Lin earned a doctor of philosophy degree in analytical chemistry from Dalhousie University in Canada. He received a master’s degree in analytical chemistry from Yunnan University and a bachelor of science degree in chemistry from Fuzhou Branch School of Jiangxi Normal College. Dr. Lin completed post-doctoral research in pharmacokinetics and metabolism at the College of Pharmacy and the Comprehensive Cancer Center of the Ohio State University.

linkedin logo 150x150 - John Lin, Ph.D.

Read Full Bio
Abdul Mutlib, Ph.D.

Abdul Mutlib, Ph.D.

Executive Vice President, DMPK Services
Abdul Mutlib, Ph.D.

Abdul Mutlib, Ph.D.

Executive Vice President, DMPK Services

Dr. Abdul Mutlib is Vice President of Drug Metabolism and Pharmacokinetics, and leads operations for this service group.  Prior to joining Frontage in 2010, he held director-level roles within drug metabolism teams at Wyeth and Pfizer. Earlier in his career, he held scientific positions on the drug metabolism teams at Hoechst-Roussel and DuPont-Merck.  With more than 20 years of experience in drug metabolism and analytical chemistry, Dr. Mutlib’s research includes application of various analytical techniques and stable isotope labeled compounds in elucidating structures of metabolites and metabolic pathways; mass spectrometry; qualitative and quantitative NMR; metabolism-mediated toxicities; reactive metabolites; phase II metabolism; drug-drug interactions; and toxicogenomics. He has published more than sixty papers in peer-reviewed journals.

Dr. Mutlib earned a bachelor’s degree in pharmacy and a doctor of philosophy degree in pharmaceutical chemistry from the University of Sydney in Australia. He completed post-doctoral fellowships at Universities of Washington and British Columbia.

linkedin logo 150x150 - Abdul Mutlib, Ph.D.

Read Full Bio
Glenn Washer, BSc, DABT <sub> (1999-2019) </sub>

Glenn Washer, BSc, DABT (1999-2019)

Executive Vice President for Global Safety and Toxicology
Glenn Washer, BSc, DABT <sub> (1999-2019) </sub>

Glenn Washer, BSc, DABT (1999-2019)

Executive Vice President for Global Safety and Toxicology

Glenn Washer, Executive Vice President for Global Safety and Toxicology, has over 35 years experience in the drug development industry.  Prior to joining Frontage, he served as President of Charles River’s Canadian preclinical businesses, and as Senior Vice President responsible for Charles River’s North America Safety Assessment business unit.  Previously he served as VP Toxicology at ITR Laboratories and at LAB Research Inc.

Glenn graduated from McGill University in 1989 and was Certified as a Diplomat of the American Board of Toxicology in 1999.  He has served as a Faculty Member with the Washington-DC-based Pharmaceutical Education & Research Institute, served on the Editorial-board-member for the International Journal of Toxicology, and has lectured on toxicology for the Society of Toxicology, the Drug Information Association, the Society of Quality Assurance, McGill University and Universite de Montreal.  In addition, he has served as a board member for multiple life-sciences industry organizations.

linkedin logo 150x150 - Glenn Washer, BSc, DABT <sub> (1999-2019) </sub>

Read Full Bio